Mini-Oral Presentation（Esophagus） 5 Recurrence/Malignancy

[EMO5-4] Introduction and treatment outcomes of immune checkpoint inhibitors as adjuvant therapy after NAC-DCF for esophageal squamous cell carcinoma

Masahiro Komoto^1,2,3,4, Takeshi Yamashita^1,2, Satoru Goto^1,2, Tomotake Ariyoshi^1,2, Kentaro Motegi¹, Akira Saito¹, Koji Otsuka³, Atsushi Horiike⁴, Takuya Tsunoda⁴, Masahiko Murakami², Takeshi Aoki¹ (1.Showa Medical University School of Medicine Department of Surgery, Division of General and Gastroenterological Surgery, Tokyo, Japan, 2.Showa Medical University Esophageal Cancer Center, 3.Showa Medical University Koto Toyosu Hospital Digestive Disease Center, 4.Showa Medical University School of Medicine Department of Medicine, Division of Oncology)

Password required to view